Several other equities research analysts have also recently commented on the company. Leerink Swann reaffirmed a buy rating on shares of Shire PLC in a research note on Saturday. Piper Jaffray Cos. set a $201.00 target price on Shire PLC and gave the stock a hold rating in a research note on Saturday. Shore Capital reaffirmed a buy rating on shares of Shire PLC in a research note on Wednesday, September 28th. Citigroup Inc. reaffirmed a buy rating on shares of Shire PLC in a research note on Tuesday, September 27th. Finally, HSBC cut Shire PLC from a buy rating to a hold rating in a research note on Monday, September 26th. Five equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $232.75.
Shares of Shire PLC (NASDAQ:SHPG) opened at 197.705 on Monday. Shire PLC has a 52 week low of $147.60 and a 52 week high of $231.32. The company has a market cap of $58.89 billion, a PE ratio of 41.086 and a beta of 1.16. The stock’s 50 day moving average price is $196.04 and its 200-day moving average price is $186.49.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. During the same period last year, the company earned $2.63 earnings per share. The firm’s revenue was up 55.9% compared to the same quarter last year. Analysts expect that Shire PLC will post $12.92 EPS for the current year.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Several hedge funds have recently added to or reduced their stakes in SHPG. Quadrant Capital Group LLC raised its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the last quarter. Canal Insurance CO bought a new stake in Shire PLC during the second quarter worth about $102,000. FTB Advisors Inc. raised its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. bought a new stake in Shire PLC during the second quarter worth about $111,000. Finally, Ropes Wealth Advisors LLC bought a new stake in Shire PLC during the second quarter worth about $114,000. Institutional investors own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.